Small extracellular vesicles (sEVs) bearing CD63 and STING-activating cargo (exoSTING)

Small extracellular vesicles bearing CD63 and STING-activating cargo, most notably exemplified by the therapeutic candidate exoSTING (CDK-002), are engineered exosomes designed for precision immunotherapy (Codiak BioSciences, 2020). These vesicles utilize the tetraspanin CD63 as a surface or internal scaffold to carry potent agonists of the Stimulator of Interferon Genes (STING) pathway (Jang et al., 2021). By delivering the cargo within a lipid bilayer, the platform enhances the stability and uptake of agonists by professional antigen-presenting cells (APCs) like dendritic cells and macrophages within the tumor microenvironment (Zhou et al., 2022). This targeted delivery triggers a robust type I interferon response, which is critical for the activation of tumor-specific T cells and the conversion of immunologically "cold" tumors into "hot" tumors (Codiak BioSciences, 2021). Unlike systemic STING agonists, which often suffer from poor pharmacokinetics and dose-limiting toxicities, these engineered vesicles provide a localized therapeutic effect with reduced systemic exposure (Mullard, 2022). Clinical development has focused on solid tumors, exploring their potential both as monotherapy and in combination with immune checkpoint inhibitors.

Other names

exoSTINGCDK-002CD63-engineered exosomesSTING-agonist loaded extracellular vesiclesCD63-positive STING-activating exosomes

Activation of the Stimulator of Interferon Genes (STING) pathway specifically within professional antigen-presenting cells (APCs) in the tumor microenvironment via exosomal delivery, leading to a potent type I interferon response and systemic anti-tumor immunity (Codiak BioSciences, 2020; Jang et al., 2021).